Moderna Inc
MRNAHealthcare|Biotechnology|USA
$48.77
-0.43 (-0.87%)
DCF (FCF)
$77.19
Tangible Book
$21.71
Upcoming Data Readouts (41)
May 2026
Est. completion
P2Respiratory Syncytial Virus
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers
NCT06143046n=360
Jun 2026
Est. completion
P1Healthy Participants
A Study to Investigate Safety and Tolerability of mRNA-0184 Administered Subcutaneously in Healthy Participants
NCT06655870n=52
Jun 2026
Est. completion
P1P2Herpes Zoster
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age
NCT05701800n=659
Jul 2026
Est. completion
P3Respiratory Syncytial Virus
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults
NCT06067230n=1,153
Aug 2026
Est. completion
P2Cytomegalovirus Infection
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.
NCT05683457n=224
Aug 2026
Est. completion
P4COVID-19
Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19
NCT07279766n=285,000
Aug 2026
Est. completion
P1Respiratory Syncytial Virus
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months
NCT05743881n=186
Sep 2026
Est. completion
P1P2Norovirus Acute Gastroenteritis
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age
NCT05992935n=1,407
Sep 2026
Est. completion
Propionic Acidemia
A Retrospective Study to Characterize Participants With Propionic Acidemia
NCT05769621n=60
Oct 2026
Est. completion
P1P2Epstein-Barr Virus Infection
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults
NCT05164094n=867
Oct 2026
Est. completion
P1Epstein-Barr Virus Infection
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants
NCT05831111n=482
Nov 2026
Est. completion
P1P2Glycogen Storage Disease
A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)
NCT05095727n=15
Dec 2026
Est. completion
P1HIV Infections
Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall Good Health in South Africa.
NCT06694753n=96
Dec 2026
Est. completion
P1P2Cystic Fibrosis
A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)
NCT05668741n=39
Dec 2026
Est. completion
P4SARS-CoV-2
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations
NCT06585241n=1,144
Jan 2027
Est. completion
P1P2Cytomegalovirus
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age
NCT05575492n=873
Jan 2027
Est. completion
Jan 2027
Est. completion
Cytomegalovirus Infections
Cytomegalovirus (CMV) Transmission and Immune Tracking (TransmIT) Study
NCT06522880n=100
Feb 2027
Est. completion
P3Acute Gastroenteritis
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis
NCT06592794n=37,864
Apr 2027
Est. completion
P1P2Bladder Cancer
A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
NCT06305767n=230
Awaiting Results (4)
Trials past primary completion date but still active — data readout may be imminent.
Apr 2026
P3
A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age
NCT07117487Jun 2023
P1
A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core)
NCT05001373